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ABSTRACT 
 
 p53 GENE MUTATION AS BIOMARKER OF RADIATION INDUCED CELL 
INJURY AND GENOMIC INSTABILITY. Gene expression profiling and its mutation has 
become one of the most widely used approaches to identify genes and their functions in the 
context of identify and categorize genes to be used as radiation effect markers including cell 
and tissue sensitivities. Ionizing radiation produces genetic damage and changes in gene 
expression that may lead to cancer due to specific protein that controlling cell proliferation 
altered the function, its expression or both. P53 protein encoded by p53 gene plays an 
important role in protecting cell by inducing growth arrest and or cell suicide (apoptosis) after 
deoxyribonucleic acid (DNA) damage induced by mutagen such as ionizing radiation. The 
mutant and thereby dysfunctional of this gene was found in more than 50% of various human 
cancers, but it is as yet unclear how p53 mutations lead to neoplastic development. Wild-type 
p53 has been postulated to play a role in DNA repair, suggesting that expression of mutant 
forms of p53 might alter cellular resistance to the DNA damage caused by radiation. Moreover, 
p53 is thought to function as a cell cycle checkpoint after irradiation, also suggesting that 
mutant p53 might change the cellular proliferative response to radiation. p53 mutations affect 
the cellular response to DNA damage, either by increasing DNA repair processes or, possibly, 
by increasing cellular tolerance to DNA damage. The association of p53 mutations with 
increased radioresistance suggests that alterations in the p53 gene might lead to oncogenic 
transformation. Current attractive model of carcinogenesis also showed that p53 gene is the 
major target of radiation. The majority of p53 mutations found so far is single base pair 
changes (point mutations), which result in amino acid substitutions or truncated forms of the 
P53 protein, and are widely distributed throughout the evolutionarily conserved regions of the 
gene. Examination of p53 mutations in human cancer also shows an association between 
particular carcinogens and characteristic patterns of these mutations. Even among cancers of 
the same organ, the mutational spectrum of the p53 gene could present different patterns by 
histologic subtype or risk factors and mutagen involved.  
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INTRODUCTION 
 
 All organisms consist of cells that multiply through cell division. An 
adult human being has approximately 100 000 billion cells, all originating 
from a single cell, the fertilized egg cell. In adults there is also an enormous 
number of continuously dividing cells replacing those dying. Before a cell 
can divide it has to grow in size, duplicate its chromosomes and separate the 
chromosomes for exact distribution between the two daughter cells. These 
different processes are coordinated in the cell cycle that is controlled by a 
number of genes that forming a network where the alteration of function in 
one of these genes will affect to all of the system. Normal cells have a 
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number of intrinsic mechanisms that involve molecular “gatekeeper” in order 
to protect them from rapid uncontrolled proliferation [1,2].  
 For all living eukaryotic organisms it is essential that the different 
phases of the cell cycle are precisely coordinated. The phases must follow in 
correct order, and one phase must be completed before the next phase can 
begin. Errors in this coordination may lead to chromosomal alterations. 
Chromosomes or parts of chromosomes may be lost, rearranged or 
distributed unequally between the two daughter cells. This type of 
chromosome alteration is often seen in cancer cells [3]. Many studies have 
revealed that human cancers are caused by the progressive accumulation of 
activating mutations in oncogenes and loss of function mutations in tumor 
suppressor genes. A subset of tumour suppressor genes function to prevent 
tumor formation or growth by inducing cell cycle arrest or apoptosis in 
response to potentially oncogenic events such as after ionizing radiation 
exposures. For example, tumor suppressor genes such as p53 and Rb encode 
proteins that are activated and restrain proliferation following expression of 
activated alleles of H-ras oncogenes [4,5]. 
 Numerous natural and men-made agents may interact with the 
biological materials such as human tissues, causing reversible deviations 
from homeostatic equilibrium or irreversible change. Death of cells resulting 
from radiation damage is probabilistic. In this case, important end-points like 
cancer will only result from secondary events, such as initiation and 
promotion occurring during regenerative cell proliferation induced by 
cytolethality. The major effects of ionizing radiation are on DNA, 
compromising cell survival, cell proliferation and proper physiological cell 
functioning. Only a small fraction of the radiation-induced molecular 
modifications occur in the DNA of the cell nucleus, but practically all 
experimental and theoretical evidence indicates that DNA, the major 
information carrier in living matter, is the critical target. To protect the 
integrity of the genetic information, most of the cellular DNA is present in 
multiple copies, and most cells have highly intricate enzyme systems to 
repair efficiently and effectively DNA damage based on information 
contained within undamaged strands. Such damage may lead to reproductive 
cell death, mutations in germ cells with possible deleterious effects in 
offspring, or to modifications in somatic cells enhancing the risk of cancer 
[6]. These genetic changes are key events in carcinogenesis. 
 There is growing acknowledgment of the usefulness of determining 
expression patterns to identify and categorize genes to use as biological 
markers. Cell and tissue sensitivity to ionizing radiation is related to many 
endogenous gene expression patterns. It is well known that various stimuli 
such as ionizing radiation produce genetic damage and changes in gene 
expression. This paper describes a biomarker or biological endpoints such as 
cellular and molecular changes in p53 gene that can be used to indicate an 
exposure to IR, representing an early event that occurs as a result of IR 
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interaction with living tissues, completed with conservatively observation on 
its function and mechanism of the p53 gene encoding P53 protein that is vital 
for controlling cancer throughout the body. 
 
p53 TUMOR SUPPRESSOR GENE 
 
 P53 or known as tumor protein 53 (TP53) was identified in 1979 by 
Arnold Levine from Princeton University, David Lane in Imperial Cancer 
Research Fund (UK), and Lloyd Old from Sloan-Kettering Memorial 
Hospital. It had been hypothesized to exist before as the target of the SV40 
virus, a strain that induced development of tumors. The p53 gene was first 
cloned in 1983 by Moshe Oren from Weizmann Institute. It was initially 
presumed to be an oncogene due to the use of mutated cDNA following 
purification of tumour cell mRNA. Its character as a tumor suppressor gene 
was finally revealed in 1989. In 1993, P53 was voted molecule of the year by 
Science magazine. This gene encompasses 20 kb of DNA; 11 exons (the first 
is non-coding) and 3.0 kb mRNA with 1179 bp open reading frame [7]. 
 P53 is a transcription factor that regulates the cell cycle and hence 
functions as a tumor suppressor. It is very important for cells in multicellular 
organisms to suppress cancer. P53 has been described as "the guardian of the 
genome", referring to its role in conserving stability by preventing genome 
mutation and instability [8]. The name is due to its molecular mass as a       
53 kilodalton (kDa) protein on SDS-PAGE. Official protein name is cellular 
tumor antigen P53 and its synonyms are tumor suppressor P53 or 
phosphoprotein P53, or antigen NY-CO-13. The human p53 gene is located 
on the human chromosome 17 (17p13.1). The location has also been mapped 
on other model animals: mouse (chromosome number 11), rat (10),  dog (5) 
and pig (12). P53 consists 393 amino acids long and has three domains : (1) 
an N-terminal transcription-activation domain (TAD), which activates 
transcription factors, (2) a central DNA-binding core domain (DBD). 
Contains zinc molecules and arginine amino acid residues, and (3) a C-
terminal homo-oligomerisation domain (OD). Tetramerization greatly 
increases the activity of P53 in vivo (Figure 1). 
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Figure 1. Representative figure of TP53 bound to a short DNA fragment. 
Protein atoms are represented as sticks, the DNA helix is in 
spacefill mode [8]. 
 
 The p53 gene is frequently mutated in human cancers and represents a 
good target for studying mutation spectra since there are > 100 potential sites 
for phenotypic mutations. Most of the mutations that deactivate p53 in cancer 
usually occur in the DBD which are recessive loss-of-function mutations.  
The mutations destroy the ability of the protein to bind to its target DNA 
sequences, and thus prevents transcriptional activation of these genes. 
Molecules of p53 with mutations in the OD dimerise with wild-type p53, and 
prevent them from activating transcription and have a dominant negative 
effect on the function of p53. Wild-type P53 is a labile protein, comprising 
folded and unstructured regions which function in a synergistic manner [9]. 
Functionally, p53 has many anti-cancer mechanisms. It can activate DNA 
repair proteins when DNA has sustained damage, it can also hold the cell 
cycle at the G1/S regulation point on DNA damage recognition and it can 
initiate apoptosis, the programmed cell death, if the DNA damage proves to 
be irrepairable. 
 Due to its highly important function, therefore, p53 is central to many 
of the cell's anti-cancer mechanisms. As stated above, it can induce growth 
arrest, apoptosis and cell senescence. In normal cells p53 is usually inactive, 
bound to the protein MDM2, which prevents its action and promotes its 
degradation by acting as ubiquitin ligase (Figure 2). Active p53 is induced 
after the effects of various cancer-causing agents such as radiation, 
oncogenes and some DNA-damaging drugs. DNA damage is sensed by 
'checkpoints' in a cell's cycle, and causes proteins such as ATM, CHK1 and 
CHK2 to phosphorylate p53 at sites that are close to or within the MDM2-
binding region of the protein. Oncogenes also stimulate p53 activation, 
mediated by the protein p14ARF. Some oncogenes can also stimulate the 
transcription of proteins which bind to MDM2 and inhibit its activity. Once 
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activated p53 transcribes several genes including one for p21 that binds to the 
G1-S/Cdk and S/Cdk complexes (molecules important for the G1/S transition 
in the cell cycle) inhibiting their activity. p53 has many anticancer 
mechanisms, and plays a role in apoptosis, genetic stability, and inhibition               
of angiogenesis [8]. Recent research has also linked the p53 and                      
RB1 pathways, via p14ARF, raising the possibility that the pathways may 
regulate each other [10]. 
 In Figure 2 below, we can see that in A, MDM2 regulates P53 protein 
in three different ways. On binding to P53 transactivation domain, it inhibits 
its transcriptional activity (1), promotes P53 degradation (2), and favors the 
export of p53 from the nucleus (3). Therefore, in the presence of MDM2, the 
P53 protein is inactivated and does not stimulate the expression of genes 
involved in apoptosis, cell cycle arrest, or DNA repair. In some tumors where 
MDM2 is overexpressed, P53 is constantly inhibited and tumor growth is 
favored. The inactivation of MDM2 in these tumors should activate the P53 
pathway and as a possible consequence should activate apoptosis. And in B, 
several strategies can be used target to MDM2 in tumors. Antisense 
oligonucleotides should decrease the cellular levels of MDM2 (Strategy 1). 
Compounds that inhibit the ubiquitin ligase activity of MDM2 could prevent 
P53 degradation (Strategy 2). p14ARF acts by blocking MDM2-dependent 
degradation and transcriptional silencing of P53. p14ARF mimics should 
therefore activate the P53 pathway (Strategy 3). Inhibitors of the P53-MDM2 
interaction should release P53 from MDM2 and as a consequence should 
activate protein P53 tumor suppressor activity (Strategy 4). 
 
                                 
 
Figure 2. Regulation of protein p53 by MDM2 in three different ways (A) 
and several strategies used to target MDM2 in tumors (B). See 
text for detail mechanism [11]. 
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 If p53 is damaged, tumor suppression is severely reduced. People who 
inherit only one functional copy of p53 will most likely develop tumors in 
early adulthood, a disease known as Li-Fraumeni syndrome. Protein p53 can 
also be damaged in cells by mutagens, increasing the likelihood that the cell 
will begin uncontrolled division. Certain pathogens such as Human 
papillomavirus (HPV) can also affect p53. HPV encodes for a protein, E6, 
which binds p53 and inactivates it. This, in synergy with the inactivation of 
another cell cycle regulator, p105RB, allows for repeated cell division 
manifested in the clinical disease of warts. In health condition p53 is 
continually produced and degraded in the cell. The degradation of p53 is 
associated with MDM2 binding. In a negative feedback loop MDM2 is itself 
induced by p53. However p53 mutant often don't induce MDM2, and are thus 
able to accumulate at very high concentrations. Mutant p53 itself can inhibit 
normal p53 [12]. 
 
 
 
Figure 3.  Representative of schematic of TP53 molecule showing the trans-
activation, evolutionarily conserved (mutation and DNA-bind), 
and tetramer and nuclear localization regions. Vertical bars show 
frequency of codons that mostly mutated (miss-sense) [7]. 
 
 Since its initation of the first gene therapy clinical trial in 1990, more 
than 2100 patients world-wide have been entered into gene therapy trials for 
such diverse diseases as viral infection, monogenic defects ans disorders such 
as cancer. There are more than 71 clinical gene therapy trials in Europe, 60% 
of which are in cancer. One of the current efforts focus on tumour supressor 
genes and manipulation of tumor growth and invasiveness, for example 
blocking angiogenesis. p53 also has a potential therapeutic use. In-vitro 
introduction of p53 in to p53-deficient cells has been shown to cause rapid 
death of cancer cells or prevention of further division. It is these more acute 
effects which hopes rest upon therapeutically [13]. Restoring its function in 
cancer cells would be a major step in curing many cancers and various 
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strategies have been proposed to do this [12]. A number of groups have found 
molecules which appear to restore proper tumour suppressor activity of p53 
in vitro by altering the conformation of p53 mutant back to an active form. 
So far, no molecules have shown to induce biological responses, but some 
may be lead compounds for more biologically active agents. A promising 
target for anti-cancer drugs is the molecular chaperone Hsp90,                       
which interacts with p53 in vivo. Importantly, normal p53 is exploited in 
radiation therapy.  
 As mentioned above that numerous antitumour therapeutic strategies 
have been proposed based on the ability to restore wild-type P53 function by 
refolding of mutant protein or relocalisation of mislocalised protein [14,15]. 
However, it is not yet clear whether continual p53 inactivation is necessary 
for continued expression of the immortalisation phenotype, i.e. whether re-
expression of wild-type levels of p53 is sufficient to halt the proliferation of 
immortalised cells with different genetic backgrounds. This must be true for 
such therapeutic strategies to be successful. The ability to conditionally 
inhibit tumour suppressor function and subsequently restore wild-type levels 
of gene expression under normal physiological control is essential to answer 
this question and can also be used to examine functional relationships 
between genes in mammalian cells. While a variety of techniques are 
available to inhibit gene function, such as genetic disruptions in mice and 
somatic cell gene disruptions in human cultured cells, these techniques are 
effectively not reversible. An alternative approach which is applicable to a 
wide variety of cell types and is potentially reversible is the delivery or 
expression of antisense constructs. 
 
p53 STATUS AND IONIZING RADIATION 
 
 Ionizing radiation induces genomic instability, which is transmitted 
through many generations after irradiation in the progeny of surviving cells 
[16,17]. Induced genomic instability manifests as the induction of various 
delayed phenotypes such as delayed lethal mutation or delayed reproductive 
death, delayed chromosomal instability, and delayed mutation induction [18]. 
Although genomic instability has been reported commonly in mammalian 
cells exposed to ionizing radiation, the mechanisms underlying the initiation 
and manifestation of radiation-induced genomic instability are not fully 
understood. Furthermore, other studies have suggested that an extranuclear 
target or a bystander effect may also be involved in the induction of 
instability [19]. Therefore, more than one mechanism may be involved in the 
initiation of radiation-induced genomic instability in survival cells. If the cell 
does not die, it may acquire genomic instability and lead to a population of 
cells with abnormally high susceptibility to gene and chromosomal instability, 
mutation and other delayed effects. Studies using inbred strains of rodents 
have clearly shown genotype-dependent differences in response to radiation 
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exposure, including susceptibility to radiation-induced cellular transformation 
and tumor formation, as well as differences in susceptibility to radiation-
induced chromosomal instability [20]. 
 More specifically, ionizing radiation causes DNA double strand breaks, 
which are the initiators for reproductive death, chromosomal aberration, 
apoptosis, and mutation. Because all of these are manifestations of radiation-
induced genomic instability, it is highly possible that delayed DNA damage is 
associated with delayed phenotypes. DNA double strand breaks are well 
known to accumulate and activate p53 [21,22]. Recent studies have described 
that DNA double strand breaks are recognized by ATM, and ATM-mediated 
phosphorylation of P53 protein accumulates and activates p53 [23]. It 
regulates transcription of the downstream genes such as p21Waf1/Cip1, gadd45, 
Reprimo, BAX, PIG-3, and p53AIP1 [7,24,25]. As a result, activated p53 
causes cell cycle arrest, apoptosis, senescence-like growth arrest, and 
involved in base excision repair [26]. It was estimated that one single DNA 
double strand break is enough to activate p53 [27], therefore, it is highly 
possible that DNA breaks arising in the progeny of surviving cells activate 
P53 protein. Moreover, radiation-induced genomic instability could be the 
driving force underlying the development of radiation-induced carcinogenesis 
by accumulating genetic alterations [28]. If p53 function is a guardian of the 
genome, there should be delayed p53 activation in the progeny of surviving 
cells [29]. 
 It is well known from many studies that cells lacking normal p53 
function exhibit no detectable G1-S arrest in response to radiation [30]. 
Following genotoxic damage, p53 is induced and acts to restrain proliferation 
by inducing the expression of genes which lead to growth arrest (such as p21) 
or apoptosis (bax). And by inhibiting proliferation following DNA damage, 
p53 action prevents the accumulation of potentially oncogenic mutations. 
Loss of p53 function has quite a varied effect on the radiosensitivity or 
chemosensitivity of tumor cells lines [31,32]. In primary mouse fibroblast 
cells which do not exhibit significant apoptosis in response to ionizing 
radiation, there is little to no preferential radioresistance of the p53 null cells 
over the normal cells [33,34].  
 p53 also functions to suppress cellular immortalisation [35,36]. Normal 
primary somatic cells are capable of undergoing a finite number of divisions 
in culture until they undergo cellular senescence, characterised by growth 
arrest, a large flat morphology and insensitivity to further mitogenic 
stimulation [37]. In contrast, many tumour cells exhibit unlimited division 
potential, indicating that they have bypassed the barriers to immortalisation, 
such as cellular senescence. p53 appears to play a direct role in controlling 
the onset of cellular senescence. p53 transcriptional activity increases with 
ageing of the cells [38], wild-type p53 activity is necessary for growth arrest 
in senescence and a high percentage of cells that escape from senescence 
have lost p53 activity [39].   
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 Persistent genomic instability or a mutator phenotype can result in the 
higher frequency of genetic alterations in cancer cells, which cannot be 
explained by random mutation [40]. Therefore, it has been hypothesized that 
radiation-induced genomic instability could be the driving force underlying 
radiation carcinogenesis [41,42]. However, some studies have shown that 
delayed DNA damage occurs in the progeny of surviving cells. Unscheduled 
DNA breaks may result in accumulation of genomic alterations. Because 
activated P53 protein in response to ionizing radiation has been thought to 
protect the integrity of the genome, delayed activation of P53 may also play a 
role as a guardian of the genome. The results of research by Clutton et al 
support that activated p53 causes delayed cell death including delayed 
apoptosis [43]. Therefore, radiation-induced genomic instability causes 
accumulation of genetic alterations, and delayed activation of p53 plays an 
indispensable role in eliminating the damaged cells and maintaining genomic 
integrity. Although several studies have described the expression of delayed 
phenotypes, the molecular mechanisms involved in delayed induction of 
DNA damage have not been determined. It was proposed that potentially 
unstable chromosome regions resulting from DNA repair of double strand 
breaks are involved in delayed DNA breakage [44]. Previous studies 
demonstrated that dicentrics were the hallmark of chromosomal instability, 
and they provided a chance to cause DNA breakage during anaphase [45]. 
Although several mechanisms may be involved in the induction of delayed 
DNA breakage, it may be explained in part by the mechanism of 
manifestation of radiation-induced genomic instability. Additional studies are 
required to clarify the mechanism that causes delayed DNA breakage for 
prevention of accumulated genetic alterations in the progeny of surviving 
cells exposed to ionizing radiation.  
 Experimentally, numerous studies have shown that ionizing radiation 
can increase the frequency and decrease the age at which tumors are observed 
in mice. This observation is apparent in animals carrying mutations in known 
tumor suppressor genes and even more so in animals deficient in genes shown 
to have a role in DNA repair and maintenance of chromosome stability. For 
example, exposure of neonatal p53-/- mice to ionizing radiation markedly 
decreases the latency to tumor formation. A similar decrease in tumor latency 
has been observed in irradiated p53+/- animals [3]. This treatment also 
increased the frequency of malignant lymphomas and decreased the incidence 
of sarcomas in these animals. In contrast, exposure of p53+/- mice to ionizing 
radiation did not alter the incidence of mammary tumors, and in fact no 
mammary tumors were identified on analysis of 33 treated p53+/- animals [3]. 
These findings indicate that exposure to ionizing radiation can decrease tumor 
latency and alter the frequency with which specific types of tumors arise in 
p53-deficient animals. These results also suggest that differential exposure of 
humans and mice to such DNA-damaging agents alone cannot explain the 
extremely low incidence of mammary tumors in p53-deficient mice as 
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compared to patients with the Li-Fraumeni syndrome. An additional 
explanation for the failure of p53-deficient mice to develop mammary tumors 
may be the increasingly frequent finding that differences in the genetic 
background on which a tumor suppressor is studied can dramatically alter the 
tumor spectrum. It has been shown that the incidence of teratocarcinomas is 
elevated in p53-/- mice on the 129/Sv genetic background as compared with 
p53-/- mice on a mixed C57BL/6-129/Sv background. The role of p53 in 
tumor suppression is further highlighted by the creation of p53−/− mice, 
which are highly cancer prone and develop a large spectrum of tumors. This 
suggests that different strains of mice contain sets of alleles that modify the 
impact of the loss of p53 in a cell type-specific manner. 
 
TYPE OF p53 MUTATION DEPENDENCE ON MUTAGEN 
 
 The assessments on the influence of mutagen on the p53 mutation 
prevalence and spectrum such as environmental tobacco smoke and 
residential radon for lung tumors, as well as ultra violet for the induction of 
skin cancer had been conducted by some researchers independently. 
Mutations in p53 are the most common defects in lung cancer and may be a 
pathway through which environmental carcinogens initiate cancer. From 
investigation by Taylor et al [46] on the detection of p53 mutations in lung 
cancers from uranium miners with high radon exposure was shown that 16 
(31%) of 52 large-cell and squamous-cell cancers from miners contained the 
same AGG to ATG transversion at codon 249, including cancers from 3 or 5 
miners who had never smoked. This specific mutation has been reported in 
only 1 of 241 published p53 mutations from lung cancers. They proposed that 
codon 249 mutation may be a marker for radon-induced lung cancer. Other 
examination conducted by Hollstein et al. [47] revealed that none of the lung 
tumors examined harbored the hotspot mutation. Five of the 50 tumors, 
however, did indeed harbor exon 7 mutations, as determined by subsequent 
mutation analysis of exon 7. These mutations were dispersed among various 
codons and may be attributable to heavy tobacco smoking in this cohort. In 
support of this interpretation, they found no mutations in exons 5-8 of the p53 
gene in 13 iatrogenic liver cancers induced by injection of Thorotrast, an 
alpha-emitting radiocontrast agent. They propose that if the p53 tumor 
suppressor gene is a target for the carcinogenic action of alpha-particle 
radiation, loss of suppressor function may occur preferentially by 
mechanisms such as intrachromosomal deletions, rather than by base 
substitution mutations. 
 Specific UV-induced mutation spectrum in the p53 gene of skin tumors 
from DNA-repair-deficient xeroderma pigmentosum patients was found by 
Dumaz et al.[48]. All the mutations were located at dipyrimidine sites, 
essentially at CC sequences, which are hot spots for UV-induced DNA 
lesions. Sixty-one percent of these mutations were tandem CC-->TT 
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mutations considered to be unique to UV-induced lesions; these mutations 
are not observed in internal human tumors. All the mutations, except two, 
must be due to translesion synthesis of unrepaired dipyrimidine lesions left 
on the nontranscribed strand. These results show the existence of preferential 
repair of UV lesions [either pyrimidine dimers or pyrimidine-pyrimidone          
(6-4) photoproducts] on the transcribed strand in human tissue. Literature 
suggests that the incidence of various tumors is determined largely by the 
genetic background on which mutations are studied. In addition, population 
studies and studies in animals suggest that environmental factors, together 
with genetic factors, determine overall risk for development of specific types 
of tumors. Environmental agents together with genetic factors can increase 
the frequency and decrease the latency of mammary tumors, leading to an 
incidence similar to that observed in Li-Fraumeni syndrome. Furthermore, it 
suggests that the risk of development of a particular type of tumor by 
individuals deficient in p53 after exposure to damaging agents can be 
influenced by modifier alleles [49]. 
 
SUMMARY 
 
 The P53 protein has been implicated in multiple cellular responses 
related to DNA damage. When working properly, P53 binds DNA to activate 
genes that direct cells with damaged DNA to cease dividing until the damage 
can be repaired. Cells with such damage include cancer cells, since all 
cancers track to genetic flaws of one kind or another, whether inherited or 
acquired. If repairs cannot be made, P53 commands the cells with damaged 
DNA to self-destruct so they are no longer a danger to the body. Alterations 
in any of these cellular responses could be related to increased genomic 
instability. The p53 gene regulates the G1 cell cycle checkpoint in response 
to DNA damage due to ionizing radiation. However, the significance of p53 
mutation in radiation sensitivity and its underlying mechanisms still remains 
unclear. To elucidate this case, some researches have measured the effects of 
p53 mutation not only on cell cycle delay, but also on apoptosis and radiation 
sensitivity using mouse cells transfected with different forms of p53 
mutations or human tissues. Other results revealed that cell survivals 
determined by clonogenic assay show that p53 mutant cells are generally 
more sensitive to ionizing radiation than cells with wild-type p53. These 
results suggest that mutant forms of p53 represent a phenotype that affects 
the radiation sensitivity and is not dependent on the apoptotic pathway.    
These findings also provide the possibility that the observed instability results  
from these DNA breaks lead to delayed chromosome rearrangements, delayed               
cell death, and so forth, many generations after irradiation and that activation               
of p53 function may eliminate cells that have potentially accumulated               
genomic alterations. In recent years, there has been an exponential increase  
in the number of p53 mutations identified in human cancers and                          
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its database consists of a list of point mutations in the p53 gene of human 
tumors and cell lines. 
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